Linear and Conformational B Cell Epitope Prediction of the HER 2 ECD-Subdomain III by in silico Methods

Mahdavi, Manijeh; Mohabatkar, Hassan; Keyhanfar, Mehrnaz; Dehkordi, Abbas Jafarian; Rabbani, Mohammad

추천

검색

자료유형: 학술저널

저자정보: Mahdavi, Manijeh (Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Isfahan University of Medical Sciences) Mohabatkar, Hassan (Department of Biotechnology, Faculty of Advanced Sciences and Technologies, University of Isfahan) Keyhanfar, Mehrnaz (Department of Biotechnology, Faculty of Advanced Sciences and Technologies, University of Isfahan) Dehkordi, Abbas Jafarian (Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Isfahan University of Medical Sciences) Rabbani, Mohammad (Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Isfahan University of Medical Sciences)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제13권 제7호

발행연도: 2012.1

수록면: 3,053 - 3,059 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor family of receptor tyrosine kinases that plays important roles in all processes of cell development. Their overexpression is related to many cancers, including examples in the breast, ovaries and stomach. Anticancer therapies targeting the HER2 receptor have shown promise, and monoclonal antibodies against subdomains II and IV of the HER2 extra-cellular domain (ECD), Pertuzumab and Herceptin, are currently used in treatments for some types of breast cancers. Since anti HER2 antibodies targeting distinct epitopes have different biological effects on cancer cells; in this research linear and conformational B cell epitopes of HER2 ECD, subdomain III, were identified by bioinformatics analyses using a combination of linear B cell epitope prediction web servers such as ABCpred, BCPREDs, Bepired, Bcepred and Elliprro. Then, Discotope, CBtope and SUPERFICIAL software tools were employed for conformational B cell epitope prediction. In contrast to previously reported epitopes of HER2 ECD we predicted conformational B cell epitopes $P1_C$: 378-393 (PESFDGDPASNTAPLQ) and $P2_C$: 500-510 (PEDECVGEGLA) by the integrated strategy and P4: PESFDGD-X-TAPLQ; P5: PESFDGDP X TAPLQ; P6: ESFDGDP X NTAPLQP; P7: PESFDGDP-X-NTAPLQ; P8: ESFDG-XX-TAPLQPEQL and P9: ESFDGDP-X-NTAPLQP by SUPERFICIAL software. These epitopes could be further used as peptide antigens to actively immune mice for development of new monoclonal antibodies and peptide cancer vaccines that target different epitopes or structural domains of HER2 ECD.

#HER2 receptor #conformational B cell epitope #bioinformatics #cancer therapy #peptide vaccine

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

이 논문의 저자 정보

Mahdavi, Manijeh

소속기관 Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Isfahan University of Medical Scien